

POLYCLONAL ANTIBODY

Catalog No. TIP-PTD-P03

Anti phospho TDP-43 (pS409)

BACKGROUND

TDP-43, a heterogeneous nuclear ribonucleoprotein, was identified as a component of ubiquitin-positive and tau-negative inclusions observed in cases of frontotemporal lobar degeneration (FTLD-U) and amyotrophic lateral sclerosis (ALS). Immunochemical analyses using antibodies generated against phospho- and non-phosphopeptides of human TDP-43 revealed that abnormally phosphorylated full-length TDP-43 (45 kDa), C-terminal fragments (~25 kDa) and smearing substances are deposited as intracellular inclusions in affected regions of FTLD-U and ALS cases. These antibodies are powerful tools for biochemical and immunohistochemical analyses of neurodegenerative diseases and for evaluation of cellular or animal models of TDP-43 proteinopathy.

Product type	Primary antibody			
Immunogen Rased in	CMDSKS(p)SGWGM, S(p):phosphoserine 409 Rabbit			
	Rabbit			
Myeloma	-			
Clone number	-			
Isotype	-			
Source	Serum			
Purification	-			
Form	Liquid. Antiserum with 0.05% NaN $_3$ as a preservative.			
Concentration	-			
Volume	100 µl			
Label	Unlabeled			
Specificity	Phospho TDP-43			
Cross reactivity	Human			
Storage	Store below -20°C. (below -70°C for prolonged storage). Aliquot to avoid cycles of freeze/thaw.			
Application notes	• Western blotting: 1/1000 - 1/5000			
Recommended dilutions	Immunohistochemistry: 1/1000 - 1/5000			
	• ELISA: 1/1000 - 1/5000			
	Other applications have not been tested. Optimal dilutions/concentrations should be determined by the end user.			
References	 Hasegawa M, Arai T, Nonaka T, Kametani F, Yoshida M, Hashizume Y, Beach TG, Buratti E, Baralle F, Morita M, Nakano I, Oda T, Tsuchiya K, Akiyama H. Phosphorylated TDP-43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis. Ann Neurol. 2008 Jun 10;64(1):60-70. PubMed: <u>18546284</u> 			

www.cosmobio.co.jp

ANTIBODY CHARACTERIZATION




Figure 1 Immunoblot analyses with pAb pS409

Perdicted molecular weight: Phosphorylated full-length TDP-43 at 45 kDa, non-phosphorylated TDP-43 at 43 kDa, - 25 kDa fragments and smearing substances in FTLD-U, ALS.




Figure 2 Immunohistochemistry of TDP-43 lesions.

PAb "pS409" recognize neuronal cytoplasmic inclusions (NCIs) and dystrophic neurites (DNs) in dentate gyrus of FTLD-U.

RELATED PRODUCTS:

Product Name	Quantity	Maker	Cat#
Anti TDP-43, phospho Ser409/410 (clone:11-9) Monoclonal Antibody	50 uL	CAC	TIP-PTD-M01
Anti TDP-43, phospho Ser409/410-1 Polyclonal Antibody	100 uL	CAC	TIP-PTD-P01
Anti TDP-43, phospho Ser409/410-2 Polyclonal Antibody	100 uL	CAC	TIP-PTD-P02
Anti TDP-43, phospho Ser409 Polyclonal Antibody	100 uL	CAC	TIP-PTD-P03
Anti TDP-43, phospho Ser410 Polyclonal Antibody	100 uL	CAC	TIP-PTD-P04
Anti TDP-43, phospho Ser403/404 Polyclonal Antibody	100 uL	CAC	TIP-PTD-P05
Anti TDP-43 N-terminus(3-12) Polyclonal Antibody	100 uL	CAC	TIP-TD-P07
Anti TDP-43 C-terminus405-414) Polyclonal Antibody	100 uL	CAC	TIP-TD-P09

For research use only, Not for diagnostic use.

